Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Prevalence of chlamydia trachomatis infection among reproductive age women in sub Saharan Africa: a systematic review and meta-analysis

  • 1Email author,
  • 2,
  • 3 and
  • 1
BMC Infectious Diseases201818:596

https://doi.org/10.1186/s12879-018-3477-y

  • Received: 25 October 2017
  • Accepted: 31 October 2018
  • Published:
Open Peer Review reports

Abstract

Background

Chlamydia trachomatis is the most common curable sexual transmitted bacterial infection in the world, including Sub-Saharan Africa. There is nil systematic review and meta-analysis on Chlamydia trachomatis infection in Sub-Saharan Africa among reproductive age women. Therefore, this study was carried out to determine the pooled prevalence of chlamydia trachomatis infection in Sub-Saharan Africa among reproductive age women.

Methods

A comprehensive literature search was conducted from biomedical data bases: Medline, PubMed, EMBASE, Google scholar, HINARI and Cochrane Library using a special index search terms (medical subject headings (MeSH), title and abstract. The Cochrane Q test and I2 statistics was used to test heterogeneity and publication bias was assessed using Begg’s and Egger’s tests. Results were presented in tables, figures and funnel plot. Data were pooled in a meta-analysis using a random effects model.

Results

Twenty-four studies were included in this meta–analysis. There was a high level of heterogeneity among studies. The pooled prevalence of Chlamydia trachomatis infection in Sub-Saharan Africa among reproductive age women was 7.8% (95% CI: 5.6–10.6).

Conclusion

This review showed that Chlamydia trachomatis infection is high in Sub-Saharan Africa among reproductive age group women. This evidence suggests that governmental and non-governmental organization shall give attention for primary prevention of this infection. Likewise, in resource limited countries policy makers, stakeholders and health care providers’ due attention for Chlamydia trachomatis specific and rapid diagnostic test, treatment in any medical out and in patient clinics for reproductive age women.

Keywords

  • Systematic review
  • Meta-analysis
  • Chlamydia trachomatis
  • Reproductive age women
  • Sub-Saharan Africa

Background

Chlamydia trachomatis is the major public health concern across the globe,and the main cause of sexual transmitted infections throughout the world, especially Sub-Saharan Africa [1]. The World Health Organization (WHO) estimated that 50 million women were newly infected with Chlamydia trachomatis worldwide, of which 34 million were in Sub-Saharan Africa and South/Southeast Asia.It is the most implicated organism that causes infertility and pelvic inflammatory disease [25].

Chlamydia trachomatis is the most common curable sexual transmitted bacterial infection in the world, with an estimated 4–5 million new cases each year [6]. WHO estimated that, the incidence of Chlamydia trachomatis is high in sub-Saharan Africa, which is more than 10 million new infection annually [2].

Chlamydial infection in women is commonly asymptomatic. Undetected and untreated Chlamydial infection can ascend upper genitalia that may cause pelvic inflammatory disease (PID), infertility, ectopic pregnancy and chronic pelvic pain [7, 8]. Chlamydial infection in women show that different clinical manifestations and associated disease like: cervicitis,endometritis, salpingitis, pelvic inflammatory disease, infertility, preterm rupture of membranes, perihepatitis, while most of women do not get medical care, because more than three forth of women are commonly asymptomatic [9].Untreated Chlamydial infection cause up to 40% of pelvic inflammatory disease cases, one in four of these will result in infertility [10].

Untreated genital infection in sub-Saharan Africa can cause up to 85% of infertility among women who seek infertility treatment and care. Undetected and untreated Chlamydial infections during pregnancy can increase risk of cervicitis, endometritis, salpingitis, pelvic inflammatory disease, infertility, perihepatitis, premature rupture of the membranes, low birth weight,chorio amnionitis, neonatal sepsis and conjunctivitis in new born [11, 12]. Whereas, the risk of developing PID after lower genital tract chlamydial infection varies considerably, up to 30%, and the risk of developing tubal infertility after PID is 10–20% [7].

Chlamydial infection can occur at any anatomical site of sexual contact including endocervix, urethra, rectum, and oropharynx, which causes pelvic inflammatory disease, infertility, ectopic pregnancy and chronic pelvic pain for women [13].

Throughout our search and knowledge, there is no systematic review and meta-analysis regarding Chlamydia trachomatis infection among reproductive age women in Sub-Saharan Africa. This study is used as an input for clinician, public health experts and stake holders for possible interventions.

Methods

Study design and search strategy

A systematic review and meta-analysis was done using published articles on prevalence of Chlamydia trachomatis in Sub-Saharan Africa. A comprehensive literature search was conducted from biomedical data bases: Medline, PubMed, EMBASE, Google scholar, HINARI and Cochrane Library using a special index search terms (medical subject headings (MeSH) “prevalence of Chlamydia trachomatis AND Sub-Saharan Africa, Chlamydia trachomatis AND reproductive age group, Chlamydia trachomatis OR Neisseria gonorrhea, Chlamydia trachomatis OR sexual transmitted infection”, title and abstract. The limit of language was English and the limit of study group was human. Searching of articles were carried out from March to October 01, 2017.

Study selection and data extraction

Cross-sectional studies published in English language from 1997 to 2017 were included. Articles that assessed prevalence of Chlamydia trachomatis infection among reproductive age group who attended ANC, family planning clinic, STI clinic, Gynecology clinic and in general population were used. Age restriction was imposed. Reproductive age group women were defined as those of age 15–49 years.

The critical appraisal was done before the extraction of data. Data extraction was carried out using the Downs and Black checklist [14]. All essential information was extracted from the final selected studies. It contains study year, population characteristics, sample size, prevalence, age, and Chlamydia trachomatis screening technique. Four authors independently reviewed the studies and inconsistencies were resolved through discussion and consensus.

Quality assessment

The quality of selected articles were assessed using 12 point scoring system based on Downs and Black check lists. These are: (clarity of objective, reported response rate which scored ≥80%, clear data collection methods and procedures, study design clearly described, sample representativeness of the entire population, the main finding of the study clearly described, suitable sampling methods, reliable measurement of outcome variable, use of appropriate statistical analysis method, and quality assurance methods). Mean quality score was used to assess the quality of included studies in the meta-analysis. Studies which scored above the mean of the quality score were grouped into the high-quality score, and those below the mean were grouped as low-quality score and not include in the meta-analysis [14].

Statistical analysis

Data entry and analysis were done using Comprehensive Meta-Analysis (version 3.1).The pooled prevalence of Chlamydia trachomatis with 95%CI was obtained using the random effects model, due to the possibility of heterogeneity among the studies.

Sub-group analysis

Sub-group analysis was conducted based on type of study population; (Community based, FCSWS Health facility based), Geographical zone; (East Africa, Middle Africa, Southern Africa and West Africa), laboratory diagnostic methods (ICT and PCR) and Year of study; (1997–2001, 2002–2006, 2007–2011, and 2012–2016).

Heterogeneity and publication bias

The heterogeneity of studies were assessed using Cochran’s Q test and I2 test statistics. A Cochran’s Q test P < 0.10 is indicated that heterogeneity between the studies [15]. The level of I2 test statistics of 25, 50 and 75% are used low, medium and high heterogeneity, respectively [16]. Publication bias was assessed by Egger’s and Begg’s test, and p-value less than 0.05 is statistically significance, and there is publication bias [17].

Results

Identified studies

A total of 93 records were retrieved through electronic database searching. Records were screened using their titles, abstracts and through full article review. Accordingly, a total of 63 articles were excluded using their title and abstract review. Thirty articles were assessed for eligibility and six article was excluded by exclusion criteria in the study. Finally, 24 articles were included in this meta-analysis (Fig. 1). The Cohran’s Q (905.3) and I2 statistics (I2 = 97.459%; p < 0.0001) revealed that high heterogeneity among studies. However, neither Egger’s test (p = 0.231) nor Begg’s test (p = 0.085) gave evidence of publication bias, which indicate to use random effects model.
Fig. 1
Fig. 1

Flow diagram of studies reviewed, screened and included

Study characteristics

The total study population size screened for Chlamydia trachomatis and involved in this systematic review and meta-analysis were 17,119.Among these, 9606 were screened at community based studies [1823], about 2638 were FCSWS [19, 20, 2428] and 4875 were at health facility based studies [2838]. The sample size of study population varied from 100 [24] to 4886 [19], and were conducted between the year 1997–2001 [19, 22, 30], 2002–2006 [25], 2007–2011 [21, 26, 31] and 2012–2016 [23, 27, 3436]. Geographically,the population screened for Chlamydia trachomatis four regions of Sub-Saharan Africa: East Africa [19, 22, 27, 3235, 37],West Africa [18, 2024, 26, 2830], Southern Africa [22, 31, 39], and middle Africa [25, 38] (Table 1).
Table 1

Chlamydia trachomatis infection among reproductive age women in different study populations in different regions of Sub Saharan Africa from 1997 to 2016 [1834]

Authors, publication year [Ref]

Country

Study population

Sample size

Prvalence(%)

Specimen

Age group

Diagnostic methods

Yirenya et al., 2014 [18]

Ghana

Community

191

6.3

Endocervical swabs

15–49

PCR

Obasi et al., 2001 [19]

Tanzania

Community

4686

2.4

Urine

15–19

PCR

Wariso et al., 2012 [20]

Nigeria

Student

400

11

Urine

16–30

PCR

Ikeme et al., 2011 [21]

Nigeria

Community

286

29.4

Blood

20–34

ICT

Buve et al., 2001 [22]

Benin

Community

962

1.3

Urine

15–49

PCR

Buve et al., 2001 [22]

Cameron

Community

1016

9.4

Urine

15–49

PCR

Buve et al., 2001 [22]

Kenya

Community

821

4.5

Urine

15–49

PCR

Buve et al., 2001 [22]

Zambia

Community

890

2.9

Urine

15–49

PCR

Arize et al., 2014 [23]

Nigeria

Students

354

30.2

Endocervical swabs

15–30

ICT

Abubakari et al.,2016 [24]

Ghana

FCSWs

100

19

Endocervical swabs

18–35

ICT

Vandepitte et al.,2007 [25]

Congo

FCSWs

502

8.4

Vaginal swabs

15–49

PCR

Opoku & Sarkodie,2014 [26]

Ghana

FCSWs

1070

4.8

vaginal swabs

18–35

ICT

Francis et al., 2014 [27]

Tanzania

FCSWs

966

12

Blood (Serum)

18–44

PCR

Apea-Kubi,2014 [28]

Ghana

OB and Gyn

465

3

Endocervical swabs

15–49

PCR

Gomes et al., 2001 [29]

Guinea-Bissau

STI and FP

200

4

Endocervical swabs

15–49

PCR

Luján et al., 2008 [30]

Mozambique

ANC

1119

4.1

urine

15–49

PCR

Kohli et al., 2013 [31]

Kenya

OPD

300

6

Vaginal swabs

18–45

ICT

Adesiji et al., 2015 [32]

Nigeria

FP and Gyn

140

0.7

Endocervical swabs

15–49

ICT

Tadesse et al., 2016 [33]

Hawassa

FP and Gyn

322

18.9

Endocervical swabs

15–49

ICT

Musa et al., 2016 [34]

Uganda

Gyn

324

26.5

Endocervical swabs

15–49

ICT

Mainaet al., 2016 [35]

Kenya

FP

261

13

Endocervical swabs

18–49

PCR

Peters et al., 2014 [36]

South Africa

ANC

603

16

Vaginal swabs

18–49

PCR

Mayaud et al., 2016 [37]

Tanzania

ANC

660

5.9

Endocervical swabs

15–49

ICT

Blankhartet al., 1999 [38]

C.A Rep.

ANC

481

6.2

Endocervical swab

15–49

PCR

ANC antenatal care, OB obstetrics, FCSHS Female commercial sex workers, FP Family planning, Gyn gynecology, Community based study (all reproductive age women who live in the study area), ICT Immuno chromatographic test and PCR Polymerase chain reaction

Meta-analysis

The analysis of 24 studies, according to the Der Simonian-Laird random-effects model. The pooled prevalence of C. trachomatis among Sub-Saharan African reproductive age women was 7.8% (95% CI: 5.6–10.6) (Fig. 2). In particular, the pooled prevalence among subgroup was 9.7% (95% CI: 5.8–16.0) in FCSWs, 7.0% (95% CI; 3.2–14.7) in community based studies, and 7.6% (95% CI; 4.7–12.3) in health facility studies. Regarding year of study, 3.8% (95% CI; 2.1–6.7) from 1997 to 2001, 8.4% (95% CI; 1.8–31.1) from 2002 to 2006, 8.8% (95% CI; 3.7–19.5) from 2007 to 2011 and11.0% (95% CI; 7.3–16.4) from 2012 to 2016, while among diagnostic method 12.8% (95% CI; 7.6–20.6) screened by ICT, and 5.8% (95% CI; 3.8–8.6) screened by PCR (Table 2). Further, subgroup analysis was done among geographical location, 8.9% (95% CI; 4.5–16.6) in East Africa, 7.2% (95% CI; 1.8–24.6) Middle Africa, 5.9% (95% CI; 1.9–16.8) Southern Africa, and 7.4% (95% CI; 4.1–13.1) in West Africa (Fig. 3).
Fig. 2
Fig. 2

The meta-analysis and forest plot presentation of C.trachomatis prevalence from 1997 to 2016 (Citations of studies used in the analysis from top to bottom [1837, 50]

Table 2

Subgroup meta-analysis of C. trachomatis prevalence estimation in Sub Saharan Africa from 1997 to 2016

 

Study parameters

Subgroup

Studies included

Prevalence %(95% CI)

I2%

P-v

C. trachomatis

study population

Community based

9

7.0(3.2–14.7)

98.678

< 0.0001

CFSWs

4

9.7(5.8–16.0)

93.168

< 0.0001

Health facility based

11

7.6(4.7–12.3)

95.763

< 0.0001

Study year

1997–2001

7

3.8(12.1–6.7)

95.289

< 0.0001

200–2006

1

8.4(1.8–31.1)

0.000

1.000

2007–2011

3

8.8(3.7–19.5)

98.852

< 0.0001

2012–2016

13

11.0(7.3–16.4)

94.753

< 0.0001

Geographical zone

Eastern

8

8.9(4.5–16.6)

98.240

< 0.0001

Middle

2

7.2(1.8–24.6)

42.502

0.187

Southern

3

5.9(1.9–16.8)

98.008

< 0.0001

Western

11

7.4(4.1–13.1)

97.181

< 0.0001

Diagnostic method

ICT

9

12.8(7.6–20.6)

97.083

< 0.0001

PCR

15

5.8(3.8–8.6)

96.230

< 0.0001

Fig. 3
Fig. 3

Prevalence of Chlamydia trachomatis in different regions of Sub-Saharan Africa among reproductive age group women, 1997–2016

Discussion

Chlamydia trachomatis is an important public health problem across the globe, including Sub-Saharan Africa. Most developed countries have implemented specific chlamydial infection control programs that vary from case management to opportunistic screening of high risk groups and annual screening program for sexually active women age < 25 years to tackle the problem. These countries decreased chlamydial infection and its complication, while in developing countries the management is still syndromic approach, and its infection and complications are still huge burden in Sub-Saharan Africa [40], because of its asymptomatic nature of the infection in most patients left unnoticed and remain untreated for longer period of time, there by transmitting the infection to their sexual partner(s). Annual screening of Chlamydia trachomatis in low income countries in all sexually active women aged < 25 years isn’t applied, whereas after complications the cost of diagnosis and treatment is high, which is compared to annual screening [7, 11]. In resource limited countries, reports of Chlamydia trachomatis represents only ‘tip of ice berg’, most of women have asymptomatic stage [11].

Based on the available data, the present study attempted to synthesize prevalence of chlamydia trachomatis in Sub-Saharan Africa among reproductive age women. In most studies the prevalence of chlamydia trachomatis is widely different from time to time, region to region, study population, study setting and type of laboratory diagnosis method.

This systematic review and meta-analysis showed that Chlamydia trachomatis among reproductive age group women in Sub-Saharan Africa was 7.8%, among diagnostic method 5.8% screened by PCR and 12.8% screened by ICT. This finding is inconsistent with WHO 2008 estimated in Africa is 2.6% [11], in 2005 is 4% [2] and global estimated is 4.2% [6].This finding is in line with systematic review in women attending antenatal care estimated prevalence of 6.9%, and the highest prevalence is predominantly at younger age < 25 years for chlamydial infection [41, 42].

In this study, the prevalence in east Africa was 8.9%. This finding is in agreement with the 6.9% reported in a systematic review and meta-analysis in East/Southern Africa, and 6.1% (95% CI: 4.0–8.3) in West/Central Africa. But, lower than a single counties reviewed studies like 4.9–14% in China, 0.1–35.9% in India, 5.7–16.2% in Thailand, 19.3% in Mongolia, and 41–44% in Bangladesh [1]. The difference might be, in this study, most of studies takes place in health facilities and around urban area, whereas studies in Asia is nationwide and screening strategy and diagnostic method quite different from Sub-Saharan Africa.

This finding is slightly higher than over all prevalence of a systematic reviewed in Australia is 4.6%, but with similar prevalence of 5.6% among adolescent and young adults [43] and in Europe, the prevalence ranged from1.7 to 17% depending on the setting, context and country [44] and this finding also slightly higher than over all prevalence in USA is 5% [45].

Over all prevalence in Australia is slightly lower than this study might be Australia women are more educated and treated at asymptomatic stage, because in Australia there is annual chlamydial infection screening for sexual active women age < 25 years.

This finding is slightly lower than with a systematic review in prison is 12.31% (95% CI:10.61, 14.01) for chlamydial infection in women, and a systematic review and meta-analysis in Iran, the pooled prevalence of the bacterium in the female population was 12.3% (95% CI: 10.6–14.2%) [46, 47]. The difference might be sociocultural, socioeconomically, screening strategy and types of laboratory diagnostic methods.

Pooled prevalence of Chlamydia trachomatis infection among commercial sex workers sub group was 9.7% (95% CI: 5.8–16.0). This study is unlikely with the population based meta-analysis study conducted in Australia, for women age < 25 years reported 5.0% (95% CI: 3.1, 6.9), among women aged < 25 years attending sexual health, family planning or youth clinics, estimated prevalence was 6.2% (95% CI:5.1, 7.4; 10), and other key finding include pooled prevalence estimates of 22.1% (95% CI: 19.0, 25.3) for indigenous women < 25 years [48].

Potential limitations of this study, due to the nature of infection, most women are asymptomatic, or treated at private or traditional, self-treated and unreported or under reported, whereas Chlamydia trachomatis is under estimated. Another important limitation is that different diagnostic methods were used in the studies included in meta-analysis. The current estimates are limited to urogenital infections. But, chlamydial infection can be rectal and oropharyngeal infection. An important limitation is the use of reproductive age women as search term. Other limitations, among further others are the heterogeneity of data and lack of reproductive tract impact data.

Implication of this study; this review generate information on prevalence of Chlamydia trachomatis infection among reproductive age women in Sub-Saharan Africa. Therefore, Sub-Saharan Africa countries and their stakeholders use this information for evidence-based intervention, to establish rapid diagnostic test and to improve their national surveillance system of Chlamydia trachomatis infection. This systematic and meta-analysis is an input for developing countries, stakeholders and policy makers to develop diagnostic and treatment programs for Chlamydia trachomatis infections. Chlamydia trachomatis is a serious public health problem in developing countries, especially Sub Saharan Africa. STI including Chlamydia trachomatis over shadowed by HIV/AIDS and given less attention [20].

Conclusion

This study revealed that chlamydia trachomatis infection in Sub-Saharan Africa among reproductive age group women is high. This evidence suggests that the government and non-government organization shall give attention for primary prevention of this infection. Likewise, in resource limited countries policy makers, stakeholders and health care providers’ due attention on Chlamydia trachomatis specific and rapid diagnostic test, treatment in any medical out and in patient clinics for reproductive age women.

Abbreviations

ANC: 

Antenatal care clinic

C.T: 

Chlamydia trachomatis

FCSWs: 

Female commercial sex workers

FP: 

Family planning

ICT: 

Immunochromatographic test

OB: 

Obstetrics

PCR: 

Polymerase chain reaction

PID: 

Pelvic inflammatory disease

STI: 

Sexual transmitted infection

WHO: 

World health organization

Declarations

Acknowledgements

We don’t have any person or organization to acknowledge.

Funding

There was no any funding or sponsoring organization for this paper.

Availability of data and materials

We do not want to share our data to use for another study.

Authors’ contributions

SH was the principal investigator who contributed to origin, the idea and design of the study, collected, entered, analyzed, interpreted the data, prepared the manuscript and acted as corresponding author. DM, ZY and ET contributed to data analysis, interpretation and drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medical Laboratory Science, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia
(2)
Department of Public Health, Hawassa College of Health Sciences, South Nations and Nationalities Peoples’ Region, Hawassa, Ethiopia
(3)
Department of Midwifery, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia

References

  1. Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis infection in pregnancy: the global challenge of preventing adverse pregnancy and infant outcomes in sub-Saharan Africa and Asia. 2016:1–21. https://doi.org/10.1155/2016/9315757.View ArticleGoogle Scholar
  2. World Health Organization. Prevalence and incidence of selected sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, Syphilis and trichomonas vaginalis: methods and results used by WHO to generate 2005 estimates. Geneva; 2011.Google Scholar
  3. Enwuru CP, Umeh SI. Asymptomatic Carriage of Chlamydia trachomatis Among Young Adults in Owerri, South East Nigeria. 2014:3:49–53.Google Scholar
  4. Finan R, Tamim H, Almawi W. Identification of chlamydia trachomatis DNA in human papillomavirus (HPV) positive women with normal and abnormal cytology. Arch Gynecol Obstet. 2002;266(3):168–71.View ArticleGoogle Scholar
  5. Okoror L, Agbonlahor D, Esumeh F, Umolu P. Prevalence of chlamydia in patients attending gynecological clinics in south eastern Nigeria. Afr Health Sci. 2007;7(1):18–24.Google Scholar
  6. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One. 2015;10(12):e0143304.View ArticleGoogle Scholar
  7. Land J, Van Bergen J, Morre S, Postma M. Epidemiology of chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update. 2009;16(2):189–204.View ArticleGoogle Scholar
  8. World Health Organization. Global incidence and prevalence of selected curable. Sex Transm Infect. 2008:19–20.Google Scholar
  9. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after chlamydia trachomatis genital infection in women. J Infect Dis. 2010;201(Suppl 2):S134–55.View ArticleGoogle Scholar
  10. World Health Organization. Global strategy for the prevention and control of sexually transmitted infections: 2006–2015: breaking the chain of transmission. Geneva; 2007.Google Scholar
  11. World Health Organization. Sexually transmitted infections (STIs): the importance of a renewed commitment to STI prevention and control in achieving global sexual and. Reprod Health. 2013:1–2.Google Scholar
  12. World Health Organization.Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. Geneva; 2013.Google Scholar
  13. Peters RP, Nijsten N, Mutsaers J, Jansen CL, Morré SA, van Leeuwen AP. Screening of oropharynx and anorectum increases prevalence of chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sex Transm Dis. 2011;38(9):783–7.View ArticleGoogle Scholar
  14. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.View ArticleGoogle Scholar
  15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.View ArticleGoogle Scholar
  16. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I 2 in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8(1):79.View ArticleGoogle Scholar
  17. Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14(5):951–7.View ArticleGoogle Scholar
  18. Yirenya-Tawiah D, Annang TN, Apea-Kubi KA, Lomo G, Mensah D, Akyeh L, et al. Chlamydia trachomatis and Neisseria gonorrhoeae prevalence among women of reproductive age living in urogenital schistosomiasis endemic area in Ghana. BMC Res Notes. 2014;7(1):349.View ArticleGoogle Scholar
  19. Obasi AI, Balira R, Todd J, Ross DA, Changalucha J, Mosha F, et al. Prevalence of HIV and chlamydia trachomatis infection in 15–19-year olds in rural Tanzania. Tropical Med Int Health. 2001;6(7):517–25.View ArticleGoogle Scholar
  20. Wariso K, Odigie J, Eyaru S. Prevalence of chlamydia trachomatis infection among female undergraduates of the University of Port Harcourt Using Strand Displacement and Amplification [SDA] technique. Nigerian Health J. 2012;12(2):35–8.Google Scholar
  21. Ikeme A, Ezegwui H, Ikeako L, Agbata I, Agbata E. Seroprevalence of chlamydia trachomatis in Enugu, Nigeria. Niger J Clin Pract. 2011;14(2):176–80.View ArticleGoogle Scholar
  22. Buve A, Weiss HA, Laga M, Van Dyck E, Musonda R, Zekeng L, et al. The epidemiology of gonorrhoea, chlamydial infection and syphilis in four African cities. AIDS. 2001;15:S79–88.View ArticleGoogle Scholar
  23. Arinze AUH, Onyebuchi NV, Isreal J. Genital chlamydia trachomatis infection among female undergraduate students of University of Port Harcourt, Nigeria. Niger Med J. 2014;55(1):9.View ArticleGoogle Scholar
  24. Abubakari A, Osei-Djarbeng SN, Larbi JA, Frimpong EH. Presence of chlamydia infection among asymptomatic female commercial sex-workers (CSWs) in the Kumasi Metropolis, Ghana. Int J Curr Microbiol App Sci. 2016;5(1):342–9.View ArticleGoogle Scholar
  25. Vandepitte JM, Malele F, Kivuvu D-M, Edidi S, Muwonga J, Lepira F, et al. HIV and other sexually transmitted infections among female sex workers in Kinshasa, Democratic Republic of Congo, in 2002. Sex Transm Dis. 2007;34(4):203–8.View ArticleGoogle Scholar
  26. Opoku B, Sarkodie Y. Prevalence of genital chlamydia and gonococcal infections in at risk women in the Kumasi metropolis, Ghana. Ghana Med J. 2010;44(1):21–4.Google Scholar
  27. Francis SC, Ao TT, Vanobberghen FM, Chilongani J, Hashim R, Andreasen A, et al. Epidemiology of curable sexually transmitted infections among women at increased risk for HIV in northwestern Tanzania: inadequacy of syndromic management. PLoS One. 2014;9(7):e101221.View ArticleGoogle Scholar
  28. Adesiji Y, Iyere S, Ogah I. Low prevalence of chlamydia trachomatis infection in women from southern Nigeria. Nitte Univ J Health Sci. 2015;5(1):4.Google Scholar
  29. Apea-Kubi KA, Yamaguchi S, Sakyi B, Kishimoto T, Ofori-Adjei D, Hagiwara T. Neisseria gonorrhoea, chlamydia trachomatis, and Treponema pallidum infection in antenatal and gynecological patients at Korle-Bu teaching hospital, Ghana. Jpn J Infect Dis. 2014;57(6):253–6.Google Scholar
  30. Gomes J, Tavira L, Exposto F, Prieto E, Catry M. Neisseria gonorrhoeae and chlamydia trachomatis infections in patients attending STD and family planning clinics in Bissau, Guinea-Bissau. Acta Trop. 2001;80(3):261–4.View ArticleGoogle Scholar
  31. Luján J, Oñate WA, Delva W, Sambola F, Claeys P, Temmerman M, et al. Prevalence of sexually transmitted infections in women attending antenatal care in Tete province, Mozambique. SAMJ. 2008;98(1):49–51.PubMedGoogle Scholar
  32. Kohli R, Konya WP, Obura T, Stones W, Revathi G. Prevalence of genital chlamydia infection in urban women of reproductive age, Nairobi, Kenya. BMC Res Notes. 2013;6(1):44.View ArticleGoogle Scholar
  33. Tadesse E, Teshome M, Amsalu A, Shimelis T. Genital chlamydia trachomatis infection among women of reproductive age attending the gynecology Clinic of Hawassa University Referral Hospital, southern Ethiopia. PLoS One. 2016;11(12):e0168580.View ArticleGoogle Scholar
  34. Musa M, Joel B, Lenard A, Joseph N, Ronald M, Julius M, et al. Prevalence and factors associated with genital chlamydial infections among women attending the Gynaecology clinic at Mbarara regional referral hospital. Prevalence. 2016;26:26–7.Google Scholar
  35. Maina AN, Kimani J, Anzala O. Prevalence and risk factors of three curable sexually transmitted infections among women in Nairobi, Kenya. BMC Res Notes. 2016;9(1):193.View ArticleGoogle Scholar
  36. Peters RP, Dubbink JH, van der Eem L, Verweij SP, Bos ML, Ouburg S, et al. Cross-sectional study of genital, rectal, and pharyngeal chlamydia and gonorrhea in women in rural South Africa. Sex Transm Dis. 2014;41(9):564–9.View ArticleGoogle Scholar
  37. Mayaud P, Uledi E, Cornelissen J, Todd J, Rwakatare M, West B, et al. Risk scores to detect cervical infections in urban antenatal clinic attenders in Mwanza, Tanzania. Sex Transm Infect. 2016;74:S139–46.Google Scholar
  38. Blankhart D, Muller O, Gresenguet G, Weis P. Sexually transmitted infections in young pregnant women in Bangui, Central African Republic. Int J STD AIDS. 1999;10(9):609–14.View ArticleGoogle Scholar
  39. Dubbink JH, De Waaij DJ, Bos M, Van der Eem L, Bébéar C, Mbambazela N, et al. Microbiological characteristics of chlamydia trachomatis and neisseria gonorrhoeae infections in South African women. J Clin Microbiol. 2016;54(1):200–3.View ArticleGoogle Scholar
  40. Low N, Cassell JA, Spencer B, Bender N, Martin Hilber A, van Bergen J, et al. Chlamydia control activities in Europe: cross-sectional survey. Eur J Public Health. 2011;22(4):556–61.View ArticleGoogle Scholar
  41. Chico RM, Mayaud P, Ariti C, Mabey D, Ronsmans C, Chandramohan D. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review. JAMA. 2012;307(19):2079–86.View ArticleGoogle Scholar
  42. Dielissen PW, Teunissen DA, Lagro-Janssen AL. Chlamydia prevalence in the general population: is there a sex difference? a systematic review. BMC Infect Dis. 2013;13(1):534.View ArticleGoogle Scholar
  43. Vajdic CM, Middleton M, Bowden FJ, Fairley CK, Kaldor JM. The prevalence of genital chlamydia trachomatis in Australia 1997–2004: a systematic review. Sex Health. 2005;2(3):169–83.View ArticleGoogle Scholar
  44. Wilson J, Honey E, Templeton A, Paavonen J, Mårdh P-A, Stary A, et al. A systematic review of the prevalence of chlamydia trachomatis among European women. Hum Reprod Update. 2002;8(4):385–94.View ArticleGoogle Scholar
  45. Scholes D, Satterwhite CL, Yu O, Fine D, Weinstock H, Berman S. Long-term trends in chlamydia trachomatis infections and related outcomes in a US managed care population. Sex Transm Dis. 2012;39(2):81–8.View ArticleGoogle Scholar
  46. Kouyoumdjian F, Leto D, John S, Henein H, Bondy S. A systematic review and meta-analysis of the prevalence of chlamydia, gonorrhoea and syphilis in incarcerated persons. Int J STD AIDS. 2012;23(4):248–54.View ArticleGoogle Scholar
  47. Ahmadi MH, Mirsalehian A, Bahador A. Prevalence of genital chlamydia trachomatis in Iran: a systematic review and meta-analysis. Pathog Glob Health. 2015;109(6):290–9.View ArticleGoogle Scholar
  48. Lewis D, Newton DC, Guy RJ, Ali H, Chen MY, Fairley CK, et al. The prevalence of chlamydia trachomatis infection in Australia: a systematic review and meta-analysis. BMC Infect Dis. 2012;12:113.View ArticleGoogle Scholar
  49. Control CfD, Prevention. Sexually Transmitted Infections in Developing Countries. Current Concepts and Strategies on Improving STI Prevention, Treatment, and Control. 2008. http://documents.worldbank.org/curated/en/867421468313772326/Sexually.
  50. Mayaud P, Uledi E, Cornelissen J, Todd J, Rwakatare M, West B, et al. Risk scores to detect cervical infections in urban antenatal clinic attenders in Mwanza, Tanzania. Sex Transm Infect. 1998;74:S139–46.PubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement